Curis (CRIS) Gets a Buy Rating from B.Riley Financial

By Ryan Adsit

In a report released today, Justin Walsh from B.Riley Financial reiterated a Buy rating on Curis (CRISResearch Report), with a price target of $22.00. The company’s shares closed last Tuesday at $6.99.

According to TipRanks.com, Walsh has 0 stars on 0-5 stars ranking scale with an average return of -27.8% and a 11.8% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Checkpoint Therapeutics, F-star Therapeutics, and Vor Biopharma.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Curis with a $23.25 average price target.

See today’s analyst top recommended stocks >>

Curis’ market cap is currently $639.8M and has a P/E ratio of -16.10. The company has a Price to Book ratio of 6.26.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.